Ceramide-Phosphatidylcholine Biomarkers for Residual Cardiovascular Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lipid-based biomarkers, such as LDL-C and HDL-C, are inadequate for accurately predicting cardiovascular events, leading to uncertain patient management and residual risk in statin-treated patients, necessitating improved methods for risk stratification and treatment targeting.
Innovation Solution
A novel biomarker combination of ceramides (Cer) and phosphatidylcholines (PC) is used to assess cardiovascular risk by monitoring specific lipid concentrations and comparing them to controls, with increased Cer and decreased PC levels indicating heightened risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional lipid-based biomarkers (LDL-C, HDL-C) are used for cardiovascular risk prediction, then the method is simple and widely established, but the prediction accuracy and reliability are insufficient
Solution Approach 1:
The patent combines multiple lipid biomarkers (ceramides, phosphatidylcholines, triglycerides, cholesterol esters) into an integrated biomarker panel to achieve more accurate cardiovascular risk prediction. This merging of multiple measurement targets resolves the contradiction by maintaining analytical precision while accepting increased system complexity for better clinical utility.
Solution Approach 2:
The invention uses a composite biomarker approach, analyzing multiple lipid species simultaneously rather than relying on a single marker. This composite strategy improves prediction accuracy by capturing the complexity of lipid metabolism, directly addressing the insufficiency of traditional single-marker approaches.
2Reliability
If statin treatment is administered to lower LDL-C, then LDL-C concentration decreases, but residual cardiovascular risk remains substantial
Solution Approach 1:
The patent implements a feedback mechanism by monitoring multiple lipid biomarkers including ceramides and phosphatidylcholines that are not affected by statin therapy. This allows detection of residual risk that persists despite LDL-C lowering, enabling clinicians to identify patients who need additional therapeutic interventions beyond statins.
Solution Approach 2:
The invention shifts the focus from monitoring only LDL-C levels to monitoring multiple lipid parameters including ceramide and phosphatidylcholine concentrations. This parameter expansion reveals treatment gaps and provides more comprehensive feedback on cardiovascular risk reduction effectiveness.
3Measurement precision
If traditional risk assessment methods are used, then the assessment process is simple, but a large proportion of high-risk patients are misclassified as intermediate risk
Solution Approach 1:
The patent merges traditional risk factors with novel lipid biomarkers (ceramides, phosphatidylcholines) to create a comprehensive risk assessment system. This combination improves risk stratification accuracy by capturing metabolic dysfunction that traditional factors miss, while the integrated approach provides a unified assessment framework.
Solution Approach 2:
The invention adds new dimensions to risk assessment by incorporating lipid species that reflect metabolic health independent of traditional risk factors. This dimensional expansion allows differentiation of high-risk patients who appear intermediate by traditional criteria, resolving the misclassification problem.
Data Source
AI summary
The present disclosure relates to methods and uses involving the determination of lipid concentrations in order to diagnose, predict, prevent and/or treat one or more cardiovascular events in a subject. The methods include analyzing lipid concentrations of a sample from the subject and comparing them to a control.